[시장보고서]동종 줄기세포 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

동종 줄기세포 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1360340

리서치사 : Transparency Market Research

발행일 : 2023년 08월

페이지 정보 : 영문 204 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,185,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,422,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 16,660,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

동종 줄기세포 시장 - 리포트의 범위

세계의 동종 줄기세포 시장에 관한 TMR의 리포트는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 연구하고 있습니다. 이 리포트는 세계의 동종 줄기세포 매출을 제공합니다. 2023년을 기준년, 2031년을 예측년으로 간주하고, 2017-2031년 기간의 시장을 분석합니다. 리포트는 2023-2031년 세계 동종 줄기세포 시장의 연평균 성장률(CAGR %)도 제공합니다.

이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 시행되고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 진행했습니다. 2차 조사에는 동종 줄기세포 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서를 참조하는 것이 포함되었습니다.

시장 스냅숏
2023년 시장 가치	9억 4,180만 달러
2031년 시장 가치	16억 달러
CAGR	6.3%

이 리포트는 세계의 동종 줄기세포 시장의 경쟁 구도를 상세 분석하고 있습니다. 세계의 동종 줄기세포 시장에서 활동하는 주요 기업이 식별되고, 이 각각은 다양한 속성의 측면에서 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 동종 줄기세포 시장의 기업 속성입니다.

시장 기업 - 경쟁 매트릭스(기업의 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- Mesoblast Limited
- Gamida Cell Ltd.
- Novartis International AG
- Cellectis SA
- Magenta Therapeutics Inc.
- Fate Therapeutics Inc.
- Cynata Therapeutics Limited
- Kiadis Pharma NV
- Takeda Pharmaceutical Company Limited
- JCR Pharmaceuticals Co., Ltd.
- Pluristem Therapeutics Inc.
- Celularity Inc.
- Lineage Cell Therapeutics Inc.
- Nohla Therapeutics Inc.
- Orchard Therapeutics plc
- 기타 주요 기업

KSA

영문 목차

영문목차

Allogeneic Stem Cell Market - Scope of Report

TMR's report on the global allogeneic stem cell market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allogeneic stem cell market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allogeneic stem cell market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the allogeneic stem cell market.

Market Snapshot
Market Value in 2023	US$ 941.8 Mn
Market Value in 2031	US$ 1.6 Bn
CAGR	6.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allogeneic stem cell market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allogeneic stem cell market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allogeneic stem cell market.

The report delves into the competitive landscape of the global allogeneic stem cell market. Key players operating in the global allogeneic stem cell market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allogeneic stem cell market profiled in this report.

Key Questions Answered in Global Allogeneic Stem Cell Market Report:

What is the sales/revenue generated by allogeneic stem cell across all regions during the forecast period?
What are the opportunities in the global allogeneic stem cell market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Allogeneic Stem Cell Market - Research Objectives and Research Approach

The comprehensive report on the global allogeneic stem cell market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allogeneic stem cell market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allogeneic stem cell market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Allogeneic Stem Cell Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
5.2. Technological Advancements
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Unmodified Stem Cell Transplant
- 6.3.2. T-cell Depleted Transplant
- 6.3.3. Cord Blood Transplant
- 6.3.4. Donor Lymphocyte Infusion (DLI)
6.4. Market Attractiveness Analysis, by Type

7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cell Source, 2017-2031
- 7.3.1. Bone Marrow
- 7.3.2. Peripheral Blood Stem Cell (PBSC)
- 7.3.3. Umbilical Cord Blood
- 7.3.4. Adipose Tissue
- 7.3.5. Others
7.4. Market Attractiveness Analysis, by Cell Source

8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
- 8.3.1. Musculoskeletal Disease
- 8.3.2. Cardiovascular Disease
- 8.3.3. Autoimmune Disease
- 8.3.4. Cancer
- 8.3.5. GvHD
- 8.3.6. Others
8.4. Market Attractiveness Analysis, by Application

9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user

9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospital
- 9.3.2. Ambulatory Surgical Center
- 9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user

10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region

11. North America Allogeneic Stem Cell Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
- 11.2.1. Unmodified Stem Cell Transplant
- 11.2.2. T-cell Depleted Transplant
- 11.2.3. Cord Blood Transplant
- 11.2.4. Donor Lymphocyte Infusion (DLI)
11.3. Market Value Forecast, by Cell Source, 2017-2031
- 11.3.1. Bone Marrow
- 11.3.2. Peripheral Blood Stem Cell (PBSC)
- 11.3.3. Umbilical Cord Blood
- 11.3.4. Adipose Tissue
- 11.3.5. Others
11.4. Market Value Forecast, by Application, 2017-2031
- 11.4.1. Musculoskeletal Disease
- 11.4.2. Cardiovascular Disease
- 11.4.3. Autoimmune Disease
- 11.4.4. Cancer
- 11.4.5. GvHD
- 11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospital
- 11.5.2. Ambulatory Surgical Center
- 11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Type
- 11.7.2. By Cell Source
- 11.7.3. By Application
- 11.7.4. By End-user
- 11.7.5. By Country/Sub-region

12. Europe Allogeneic Stem Cell Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
- 12.2.1. Unmodified Stem Cell Transplant
- 12.2.2. T-cell Depleted Transplant
- 12.2.3. Cord Blood Transplant
- 12.2.4. Donor Lymphocyte Infusion (DLI)
12.3. Market Value Forecast, by Cell Source, 2017-2031
- 12.3.1. Bone Marrow
- 12.3.2. Peripheral Blood Stem Cell (PBSC)
- 12.3.3. Umbilical Cord Blood
- 12.3.4. Adipose Tissue
- 12.3.5. Others
12.4. Market Value Forecast, by Application, 2017-2031
- 12.4.1. Musculoskeletal Disease
- 12.4.2. Cardiovascular Disease
- 12.4.3. Autoimmune Disease
- 12.4.4. Cancer
- 12.4.5. GvHD
- 12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospital
- 12.5.2. Ambulatory Surgical Center
- 12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Type
- 12.7.2. By Cell Source
- 12.7.3. By Application
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region

13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
- 13.2.1. Unmodified Stem Cell Transplant
- 13.2.2. T-cell Depleted Transplant
- 13.2.3. Cord Blood Transplant
- 13.2.4. Donor Lymphocyte Infusion (DLI)
13.3. Market Value Forecast, by Cell Source, 2017-2031
- 13.3.1. Bone Marrow
- 13.3.2. Peripheral Blood Stem Cell (PBSC)
- 13.3.3. Umbilical Cord Blood
- 13.3.4. Adipose Tissue
- 13.3.5. Others
13.4. Market Value Forecast, by Application, 2017-2031
- 13.4.1. Musculoskeletal Disease
- 13.4.2. Cardiovascular Disease
- 13.4.3. Autoimmune Disease
- 13.4.4. Cancer
- 13.4.5. GvHD
- 13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospital
- 13.5.2. Ambulatory Surgical Center
- 13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Type
- 13.7.2. By Cell Source
- 13.7.3. By Application
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region

14. Latin America Allogeneic Stem Cell Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
- 14.2.1. Unmodified Stem Cell Transplant
- 14.2.2. T-cell Depleted Transplant
- 14.2.3. Cord Blood Transplant
- 14.2.4. Donor Lymphocyte Infusion (DLI)
14.3. Market Value Forecast, by Cell Source, 2017-2031
- 14.3.1. Bone Marrow
- 14.3.2. Peripheral Blood Stem Cell (PBSC)
- 14.3.3. Umbilical Cord Blood
- 14.3.4. Adipose Tissue
- 14.3.5. Others
14.4. Market Value Forecast, by Application, 2017-2031
- 14.4.1. Musculoskeletal Disease
- 14.4.2. Cardiovascular Disease
- 14.4.3. Autoimmune Disease
- 14.4.4. Cancer
- 14.4.5. GvHD
- 14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospital
- 14.5.2. Ambulatory Surgical Center
- 14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Type
- 14.7.2. By Cell Source
- 14.7.3. By Application
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region

15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
- 15.2.1. Unmodified Stem Cell Transplant
- 15.2.2. T-cell Depleted Transplant
- 15.2.3. Cord Blood Transplant
- 15.2.4. Donor Lymphocyte Infusion (DLI)
15.3. Market Value Forecast, by Cell Source, 2017-2031
- 15.3.1. Bone Marrow
- 15.3.2. Peripheral Blood Stem Cell (PBSC)
- 15.3.3. Umbilical Cord Blood
- 15.3.4. Adipose Tissue
- 15.3.5. Others
15.4. Market Value Forecast, by Application, 2017-2031
- 15.4.1. Musculoskeletal Disease
- 15.4.2. Cardiovascular Disease
- 15.4.3. Autoimmune Disease
- 15.4.4. Cancer
- 15.4.5. GvHD
- 15.4.6. Others
15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospital
- 15.5.2. Ambulatory Surgical Center
- 15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Type
- 15.7.2. By Cell Source
- 15.7.3. By Application
- 15.7.4. By End-user
- 15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
- 16.3.1. Mesoblast Limited
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Gamida Cell Ltd.
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Novartis International AG
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. Cellectis SA
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. Magenta Therapeutics Inc.
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Fate Therapeutics Inc.
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Cynata Therapeutics Limited
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Kiadis Pharma N.V.
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Takeda Pharmaceutical Company Limited
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. JCR Pharmaceuticals Co., Ltd.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Product Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview
- 16.3.11. Pluristem Therapeutics Inc.
  - 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.11.2. Product Portfolio
  - 16.3.11.3. Financial Overview
  - 16.3.11.4. SWOT Analysis
  - 16.3.11.5. Strategic Overview
- 16.3.12. Celularity Inc.
  - 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.12.2. Product Portfolio
  - 16.3.12.3. Financial Overview
  - 16.3.12.4. SWOT Analysis
  - 16.3.12.5. Strategic Overview
- 16.3.13. Lineage Cell Therapeutics Inc.
  - 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.13.2. Product Portfolio
  - 16.3.13.3. Financial Overview
  - 16.3.13.4. SWOT Analysis
  - 16.3.13.5. Strategic Overview
- 16.3.14. Nohla Therapeutics Inc.
  - 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.14.2. Product Portfolio
  - 16.3.14.3. Financial Overview
  - 16.3.14.4. SWOT Analysis
  - 16.3.14.5. Strategic Overview
- 16.3.15. Orchard Therapeutics plc
  - 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.15.2. Product Portfolio
  - 16.3.15.3. Financial Overview
  - 16.3.15.4. SWOT Analysis
  - 16.3.15.5. Strategic Overview
- 16.3.16. Other Prominent Players
  - 16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.16.2. Product Portfolio
  - 16.3.16.3. Financial Overview
  - 16.3.16.4. SWOT Analysis
  - 16.3.16.5. Strategic Overview

한글목차

동종 줄기세포 시장 - 리포트의 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장의 분석과 예측 : 유형별

제7장 세계 시장의 분석과 예측 : 세포원별

제8장 세계 시장의 분석과 예측 : 용도별

제9장 세계 시장의 분석과 예측 : 최종사용자별

제10장 세계 시장의 분석과 예측 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 구도